• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lantern Pharma Inc (NQ: LTRN )

    3.470 +0.130 (+3.89%)
    Streaming Delayed Price Updated: 12:03 PM EDT, Oct 28, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 21,786
    Open 3.380
    Bid (Size) 3.460 (1)
    Ask (Size) 3.490 (98)
    Prev. Close 3.340
    Today's Range 3.290 - 3.490
    52wk Range 2.380 - 11.99
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
    From Lantern Pharma Inc.
    Via Business Wire
    Lantern Pharma to Host & Participate in Two Public Webinars During October
    From Lantern Pharma Inc.
    Via Business Wire

    Performance

    YTD
    -16.79%
    -16.79%
    1 Month
    -8.08%
    -8.08%
    3 Month
    -24.73%
    -24.73%
    6 Month
    -29.61%
    -29.61%
    1 Year
    +33.46%
    +33.46%

    More News

    Read More
    Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
    From Lantern Pharma Inc.
    Via Business Wire
    Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers
    From Lantern Pharma Inc.
    Via Business Wire
    LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024
    Via InvestorPlace
    Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates
    From Lantern Pharma Inc.
    Via Business Wire
    Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024
    From Lantern Pharma
    Via Business Wire
    Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort
    From Lantern Pharma
    Via Business Wire
    Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET
    From Lantern Pharma Inc.
    Via Business Wire
    Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
    From Lantern Pharma
    Via Business Wire
    Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
    From Lantern Pharma Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    LTRN Stock Earnings: Lantern Pharma Misses EPS for Q1 2024
    Via InvestorPlace
    Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
    From Lantern Pharma Inc.
    Via Business Wire
    Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
    From Lantern Pharma Inc.
    Via Business Wire
    Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
    From Lantern Pharma Inc.
    Via Business Wire
    3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire
    Via InvestorPlace
    Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
    From Lantern Pharma Inc.
    Via Business Wire
    Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
    From Lantern Pharma Inc.
    Via Business Wire
    Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    Exposures Artificial Intelligence Product Safety
    AI Sector Stalling: Only 4 Of 7 Categories Went Up In March
    Via Talk Markets
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Six Of Seven AI Stock Categories Increased This Week
    Via Talk Markets
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.